The research questions, method, and participant inclusion criteria described below may "evolve" as institutional and organizational partners, voting participants and researchers help "co-create" the approach.
Non-optimized medication therapies affect millions of lives and cost as much as $528 billion in potentially avoidable healthcare spending in the US alone each year.
In this study, we will bring together key leaders from across the US to co-create an enhanced infrastructure, including enhanced payment and practice models, to accelerate development and implementation of products and services to optimize medication therapies for all people.
What is unique about this study is the use of new and emerging sciences - collaboration sciences, service-dominant logic, implementation science, network science, population health sciences, and information sciences - to help accelerate processes of developing and implementing transformational innovations to help address this challenge.
Optimizing medications is, arguably, one of the most significant areas of opportunity for creating new value (e.g. improving cost, quality, outcomes and patient satisfaction) in the US healthcare sector.
Physicians, pharmacists, nurses and others are demonstrating increasing success in optimizing medications use by working in patient-centered care teams.
Federal and state policymakers have a growing interest in supporting action to protect and strengthen the health of the population following the COVID-19 pandemic.
There is growing public and professional recognition of the value to care teams that US pharmacists and pharmacies can provide
Delivery of tests, vaccines and patient support during the COVID-19 pandemic significantly strengthened public awareness of the value of pharmacists and pharmacies.
Ability to move and share pharmacy-related data digitally is advancing rapidly, with support from agencies like the ONC.
Pharmacists will be increasingly needed to support delivery of new medication related products and services through innovations in pharmacogenomics, digital therapeutics and other advanced medication therapies.
Based on what is currently known or believed, and after taking into account today's payment, practice, measurement, technology, policy and research environments, please answer the following questions.
Question 1. Population Health Needs
Who are the key population groups that need enhanced services to optimize their medication therapies? What are their specific needs? In developing your answers:
Please consider traditional medications, over the counter medicines, vaccines, pharmacogenomics and digital therapeutics.
Please consider Health Equity and Empowerment. How will the enhanced infrastructure support health equity and empowerment for all people as an overarching priority? How will the participants involved in the regatta reflect these priorities?
Question 2. New/Enhanced Services Needed for Patients?
What new or enhanced services need to be delivered to populations to meet these needs? How would these enhanced services work? What would be done? By whom? When, where and how? How long would they take? How would they be adapted to different types of customers?
Question 3. Infrastructure Enhancements Needed to Support Services?
What key enhancements to existing US infrastructure need to be developed and implemented that could allow all US stakeholders to work together more efficiently and effectively to develop and deliver enhanced or new services to better meet these population health needs?
a. Payment and Incentive model enhancements?
b. Measurement model enhancements?
c. Digital Technology and Interoperability enhancements?
d. Policy enhancements?
e. New Non-Profit Utility(ies)?
f. Other enhancements?
Question 4. Research and Action Priorities
What are the priority research studies are needed to move forward to develop and implement these services and enhancements?
3.1 Research Priorities
3.2 Action Priorities
Output 4. Top 10 ranked list(s)
Want More Details?
Research Regatta Method
Overview of Method
A Research Regatta is a way to bring together leaders and researchers from multiple sectors and disciplines to "row together" towards a shared goal in society. The Regatta Model works by organizing people into a series of virtual "boats," with 7-15 people in each. Boats are organized to race in "sections". These include stakeholder sections (e.g. pharmacists, physicians, health plans, mixed crews and so on) and functional sections (e.g. services and operations, payment and finance, technology, policy, measures, and so on). each boat uses nominal group technique to brainstorm, refine and vote to develop consensus solutions to problems. Answers are then refined by multiple crews working together over several rounds.
The anticipated results are broadly supported, actionable plans for developing and implementing enhanced infrastructure and transformational innovations to improve the health of people in society.
Regatta Timeline: May - January, 2021*
Timelines may be modified from time to time to accommodate input from participants.
Participant Selection Criteria
Medications and related therapies are prescribed to virtually everyone in the US at one time or another. They are an integral part of healthcare delivery and are used to treat many different types of illness. For this reason, we believe it is important to include all key stakeholders involved in medication therapies in this study. The selection criteria is designed to provide balanced representation from nationally recognized leaders from leading entities in multiple categories. Participants at 3 levels (network, organization and individual) are invited for each category.
Three Levels of Participation
Institutional level participants in this study include government agencies, national associations, technology platforms and educational networks that have a leadership position in maintaining institutions - rules, standards and customs - that support the field. These entities are necessary and important participants in the study. Once they join, they are also asked to help to identify and invite other key organizations and leaders to support comprehensive representation in the study.
Organizational level participants in this study are businesses and non-profits that help lead the field, based on their market-size and/or influence. For each category, a set of leading organizations with the collective ability to shape the field are identified for invitation.
At an individual level, participants in this study are senior leaders and established researchers from the above noted institutions and organizations, as well as supporting staff, researchers and students they may wish to invite.
Stakeholder Categories Invited
Research Universities / Researchers
Physicians, NPs, Dentists and Other Clinicians
Pharmaceuticals and Other Product Manufacturers
Health Plans and Plan Sponsors
Health Systems / Clinics / IDN / VA/DOD
Senior Care / SNFs
Standards and Measures Organizations
Health IT / Interoperability / Digital Health
Policy Partners (Federal, State and Local)
Health Equity and Empowerment - considered across all areas
Investors, Foundations and other Funding Partners
Types of Individuals Invited
CEOs, Presidents and Other Executive Leaders
Strategy and Innovation Leadership
Service and operations leadership
Finance and payment leadership
Information Technology Leadership
Supporting staff invited by voting participants.
Established researchers from nationally recognized research institutions, plus additional faculty, students, and staff they invite to support them.
Minimum Number of Panels (Boats)
The study design calls for a minimum target of 15-20 panels (boats) with 7-15 participants per boat from the various sectors noted. In general, more boats are better, as they will strengthen diversity of perspectives. If more than 15 people show up, they can be split into two boats. Insights from each boat will be combined, and analyzed qualitatively and statistically, to generate valid data about the overall model design and plans. The final number of boats will be contingent on commitments from invited institutions and organizations and availability of sponsorship funding.
Sponsorship Selection Criteria
A diverse set of sponsors will be invited to support the Regatta. Care will be taken to ensure that no one sponsor has an undue influence on the overall process or findings. Objectivity will be strengthened by allowing many sponsors to co-sponsor the Regatta with the understanding that we are all working together to achieve a public good - in this case optimizing medication therapies for US populations as quickly as possible. The sponsorships will help the researchers support an open, transparent, collaborative process leading to findings that can be broadly supported.
Want to Learn More About the Inclusion Criteria for this Study?
Regatta website, including
Literature reviews in the Learning Center
Compilation of "innovator insights"
Posting of innovations in an Innovation Lab
Regatta panel meetings - 15-20 or more "boats"
Summit event - compiling evidence, determining next steps
1 or more academic paper submissions
1 or more conference presentations
Next step research plans published on website
A Collaboratively Funded Study
This is a collaboratively funded research study. Partial support is provided by the National Science Foundation Center for Health Organization Transformation at University of Louisville. Each organization that can is asked to provide additional support to help cover costs of conducting a high-quality study with multiple researchers in states across the US. Please support the Regatta at the recommended level your organization can support.
Executive Supporter: $5,000
Strategic Supporter: $10,000
Anchor Supporter: $25,000
Note: All invited organizations are encouraged to participate, regardless of ability to provide sponsorships. We understand not all organizations may be able to provide funding support.
Why a Collaborative Sponsorship Funding Model?
Please support the study at a recommended level if you can to help this study be as successful as possible.